The FDA has made significant strides in the fight against gonorrhea by approving two new oral therapies, Nuzolvence (zoliflodacin) and Blujepa (gepotidacin), marking the first new antibiotics for this infection in decades. These treatments aim to combat the growing issue of drug-resistant gonorrhea, offering hope for more effective management of this sexually transmitted infection. Clinical trials have shown that the single-dose oral treatment is effective against drug-resistant strains, potentially treating millions of cases worldwide. The approvals reflect a crucial step forward in addressing the challenges posed by antibiotic resistance.